空腹C肽联合FIB-4指数对2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化进展的评估价值

任桂晶; 韩琳; 秦少游; 王心刚; 周长玉

doi:10.3969/j.issn.1001-5256.2018.12.015

空腹C肽联合FIB-4指数对2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化进展的评估价值

DOI: 10.3969/j.issn.1001-5256.2018.12.015

1. 吉林大学中日联谊医院消化内科
2. 吉林大学中日联谊医院放射科

详细信息

中图分类号: R587.1;R575.5
计量
- 文章访问数: 2090
- HTML全文浏览量: 81
- PDF下载量: 311
- 被引次数: 14
出版历程
- 出版日期: 2018-12-20

Clinical significance of fasting C-peptide combined with fibrosis-4 index in assessing the progression of liver fibrosis in type 2 diabetic patients with nonalcoholic fatty liver disease

摘要

摘要: 目的利用空腹C肽联合FIB-4指数评估2型糖尿病（T2DM）合并非酒精性脂肪性肝病（NAFLD）患者肝纤维化进展状况。方法选取2016年5月-2017年7月于吉林大学中日联谊医院体检中心进行体检并诊断为T2DM合并NAFLD的患者513例,根据FibroScan测得的肝脏组织硬度值（LSM）,将患者分为非进展性肝纤维化组（466例）及进展性肝纤维化组（47例）。记录所有患者的年龄、腹围、血压、BMI、PLT计数、空腹血糖、空腹C肽、肝功能、血脂、尿酸、FIB-4指数,2组患者计量资料的比较,采用t检验或Mann-Whithey U检验,计数资料的比较采用χ2检验,用logistic回归方法筛选危险因素并构建联合诊断模型,采用受试者工作特征曲线对诊断效能进行评估。结果进展性肝纤维化组患者的年龄、AST水平、FIB-4指数、空腹C肽水平分别为51（49～55）岁、28. 9（25. 7～35. 1） U/L、0. 97（0. 75～1. 34）、（2. 64±0. 66） ng/ml,均高于非进展性肝纤维化组的50 （47～53）岁、27. 1（22. 2～32. 8） U/L、0. 85...
- 非酒精性脂肪性肝病 /
- 糖尿病,2型 /
- 肝硬化 /
- C肽
Abstract: Objective To investigate the clinical significance of fasting C-peptide combined with fibrosis-4 (FIB-4) index in assessing the progression of liver fibrosis in patients with type 2 diabetes mellitus (T2 DM) and nonalcoholic fatty liver disease (NAFLD) . Methods A total of 513 patients who underwent physical examination in Physical Examination Center of China-Japan Union Hospital of Jilin University from May 2016 to July 2017 and were diagnosed with T2 DM and NAFLD were enrolled, and according to liver stiffness measurement (LSM) obtained by FibroScan, they were divided into non-progressive liver fibrosis group with 466 patients and progressive liver fibrosis group with 47 patients. Related data were recorded, including age, abdominal circumference, blood pressure, body mass index, platelet count, fasting blood glucose, fasting C-peptide, liver function, blood lipids, uric acid, and FIB-4 index. The t-test or the Mann-Whitney U test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Logistic regression was used to establish a joint diagnosis model. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of different indicators. Results Compared with the non-progressive liver fibrosis group, the progressive liver fibrosis group had significantly higher age [51 (49-55) years vs 50 (47-53) years, P = 0. 021], aspartate aminotransferase level [28. 9 (25. 7-35. 1) IU/L vs 27. 1 (22. 2-32. 8) IU/L, P = 0. 017], FIB-4 index [0. 97 (0. 75-1. 34) vs 0. 85 (0. 62-1. 19) , P = 0. 030], and fasting C-peptide level [2. 64 ± 0. 66 ng/ml vs 2. 33 ± 0. 79 ng/ml, P = 0. 004]. Fasting C-peptide (odds ratio [OR]= 1. 77, 95% confidence interval [CI]: 1. 201-2. 633, P = 0. 004) and FIB-4 index (OR = 2. 14, 95% CI: 1. 248-3. 613, P = 0. 004) were independent risk factors for progressive liver fibrosis in patients with T2 DM and NAFLD. Fasting C-peptide combined with FIB-4 index had an area under the ROC curve of 0. 730 (> 0. 70) in evaluating progressive liver fibrosis in patients with T2 DM and NAFLD. Conclusion Fasting C-peptide combined with FIB-4 index has a certain value in the diagnosis of progressive liver fibrosis in patients withT2 DM and NAFLD.
- fatty liver /
- diabetes mellitus, type 2 /
- liver cirrhosis /
- C-peptide

HTML全文

参考文献(20)

[1] LEITE NC, VILLELA-NOGUEIRA CA, PANNAIN V LN, et al.Histopathological stages of nonalcoholic fatty liver disease in type 2diabetes:Prevalences and correlated factors[J]. Liver Int, 2011, 31 (5) :700-706.

[2] Chinese Society of Diabetes, Chinese Medical Association. The guidelines of the prevention and treatment for type 2 diabetes in China (2013 Edition) [J]. Chin J Diabetes Melitus, 2014, 7 (6) :447-498. (in Chinese) 中华医学会糖尿病学分会.中国2型糖尿病防治指南 (2013年版) [J].中华糖尿病杂志, 2014, 7 (6) :447-498.

[3] KWOK R, CHOI KC, WONG G LH, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J].Gut, 2016, 65 (8) :1359-1368.

[4] DIXON JB, BHATHAL PS, O'BRIEN PE. Nonalcoholic fatty liver disease:Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese[J]. Gastroenterology, 2001, 121 (1) :91-100.

[5] Chinese Society of Hepatology, Department of Fatty Liver and Alcoholic Liver Diseases, Chinese Medical Association. The guidelines of the diagnosis and treatment for non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[6] GRIMALDI A, HEURTIER A. Diagnostic criteria for type 2 diabetes[J]. Rev Prat, 1999, 49 (1) :16-21.

[7] ONG JP, YOUNOSSI ZM. Epidemiology and natural history of NAFLD and NASH[J]. Clin Liver Dis, 2007, 11 (1) :1-16.

[8] WONG V WS, VERGNIOL J, WONG G LH, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J]. Hepatology, 2010, 51 (2) :454-462.

[9] RAFIQ N, BAI C, FANG Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver[J]. Clin Gastroenterol Hepatol, 2009, 7 (2) :234-238.

[10] ANGULO P, HUI JM, MARCHESINI G, et al. The NAFLD fibrosis score:A noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology, 2007, 45 (4) :846-854.

[11] Chinese Society of Hepatology, Department of Fatty Liver and Alcoholic Liver Diseases, Chinese Medical Association, Expert Committee on Fatty Liver Diseases. The guidelines of prevention and treatment for nonalcoholic fatty liver diseases (Updated 2018) [J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.

[12] LEI JW, TAN BB, LI WB, et al. Value of transient elastography measured with Fibro Touch in the diagnosis of liver fibrosis in chronic hepatitis patients with hepatocellular carcinoma[J]. Chin J Med Offic, 2017, 45 (9) :930-933. (in Chinese) 雷洁雯, 谭碧波, 李万斌, 等. Fibro Touch瞬时弹性成像诊断慢性乙型肝炎合并肝癌患者肝纤维化程度应用研究[J].临床军医杂志, 2017, 45 (9) :930-933.

[13] MAK KM, MEI R. Basement membrane type IV collagen and laminin:An overview of their biology and value as fibrosis biomarkers of liver disease[J]. Anat Rec, 2017, 300 (8) :1371-1390.

[14] AUMAILLEY M. The laminin family[J]. Cell Adh Migr, 2012, 7 (1) :48-55.

[15] QI X, LI H, CHEN J, et al. Serum liver fibrosis markers for predicting the presenceof gastroesophageal varices in liver cirrhosis:A retrospective cross-sectional study[J]. Gastroent Res Pract, 2015:1371-1350.

[16] YANG EN, CAO WK. Research in the process of non invasive diagnosis of liver fibrosis[J] J Clin Hepatol, 2017, 33 (11) :2209-2213. (in Chinese) 杨二娜, 曹武奎.肝纤维化无创诊断的研究进展[J].临床肝胆病杂志, 2017, 33 (11) :2209-2213.

[17] TANG N, ZHANG Y, LIU Z, et al. Correlation analysis between four serum biomarkers of liver fibrosisand liver function in infants with cholestasis[J]. Biomedical Reports, 2016, 5 (1) :107-112.

[18] LIU T, WANG X, KARSDAL MA, et al. Molecular serum markers of liver fibrosis[J]. Biomark Insights, 2012, 7:105-117.

[19] CHANG PE, GOH G BB, NGU JH, et al. Clinical applications, limitations and future role of transient elastography in the management of liver disease[J]. World J Gastrointest Pharmacol Ther, 2016, 7 (1) :91-106.

[20] IMAJO K, KESSOKU T, HONDA Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography[J]. Gastroenterology, 2016, 150 (3) :626-637.

施引文献

期刊类型引用(12)

1.	张倩落，马赟，杨国祥，王宏利，贾庶捷. 安络化纤丸联合硫普罗宁治疗慢性乙型肝炎肝硬化的临床研究. 现代药物与临床. 2024(02): 412-417 . 百度学术
2.	谢娇娇，何燕芳，马燕花，郭才，郑兰兰. 肝硬化患者血清高迁移率族蛋白B水平变化及其与肠黏膜通透性的相关性. 山东医药. 2024(15): 9-12 . 百度学术
3.	刘俊香，毕泗朕. 血清GP73、HMGB1、FLP1、sST2与慢性乙型病毒性肝炎患者 HBV-DNA载量、肝功能及肝纤维化标志物的相关性分析. 检验医学与临床. 2023(06): 787-791 . 百度学术
4.	陆燕夏，唐秀娇，郑成芳，王月琴. 血清ANGPTL2、sVAP-1、HMGB1在慢性乙型肝炎诊断中的价值. 国际检验医学杂志. 2022(11): 1325-1328 . 百度学术
5.	陈婷婷，储建华，杨丽，周宝勤. HMGB-1、PDGF-BB和PTAR水平对慢性乙型肝炎肝硬化病情程度和疾病预后的评估价值. 现代消化及介入诊疗. 2022(10): 1318-1322 . 百度学术
6.	徐静，张凤岐，王聪，陈磊，郭锋. 血清miR-223、HMGB1与乙肝患者HBV-DNA载量和肝功能的关系研究. 国际病毒学杂志. 2021(04): 332-335 . 百度学术
7.	何伟锋. 研究慢性乙型肝炎合并非酒精性脂肪性肝病患者的肝组织纤维化水平与脂质负荷的关系. 名医. 2020(09): 58-59 . 百度学术
8.	许日新，林俊芳，邓雅丽. 慢性乙型肝炎肝硬化患者微生态制剂联合抗病毒药物治疗效果及机体免疫功能的变化. 慢性病学杂志. 2020(12): 1798-1801 . 百度学术
9.	杜刚，王永利，冯雅. 腹腔镜下左半肝切除术与恩度联合治疗肝癌患者的效果及对血清HMGB1和TK1水平的影响. 临床和实验医学杂志. 2019(17): 1874-1879 . 百度学术
10.	邓崇君，陆文烈. 探讨替比夫定与恩替卡韦治疗乙型肝炎病毒感染的临床疗效及对炎症因子的影响. 北方药学. 2019(12): 116-117 . 百度学术
11.	Chunli TANG，Jiangcun WEI，Zhen XIE，Meiyan QIU，Jiabao MA，Fengxian ZHAO，Hongxia CHEN. Water Extraction Process of Chinese Herbal Compound Man Gan Ning. Medicinal Plant. 2019(06): 60-65 . 必应学术
12.	姚传霞，汪茂荣. 高迁移率族蛋白-1的生物学特性及其在HBV相关肝病发生、发展和治疗中的作用. 临床肝胆病杂志. 2019(12): 2788-2792 . 本站查看